Literature DB >> 10585254

Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function.

S Laín1, D Xirodimas, D P Lane.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10585254     DOI： 10.1006/excr.1999.4672

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN： 0014-4827            Impact factor:   3.905


× No keyword cloud information.
  19 in total

1.  p53 and MDM2 are involved in the regulation of osteocalcin gene expression.

Authors:  Hankui Chen; Kevin Kolman; Natalie Lanciloti; Michael Nerney; Emily Hays; Chet Robson; Nalini Chandar
Journal:  Exp Cell Res       Date:  2012-03-03       Impact factor: 3.905

2.  Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement.

Authors:  Sabela Bobillo; Pau Abrisqueta; Cecilia Carpio; Priyanka Raheja; Josep Castellví; Marta Crespo; Francesc Bosch
Journal:  Haematologica       Date:  2017-12-14       Impact factor: 9.941

3.  Identification of three functions of the adenovirus e4orf6 protein that mediate p53 degradation by the E4orf6-E1B55K complex.

Authors:  E Querido; M R Morrison; H Chu-Pham-Dang; S W Thirlwell; D Boivin; P E Branton; M R Morisson
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 4.  Strategies for manipulating the p53 pathway in the treatment of human cancer.

Authors:  T R Hupp; D P Lane; K L Ball
Journal:  Biochem J       Date:  2000-11-15       Impact factor: 3.857

5.  Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study.

Authors:  R Lev Bar-Or; R Maya; L A Segel; U Alon; A J Levine; M Oren
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

6.  An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells.

Authors:  Ingeborg M M van Leeuwen; Bhavya Rao; Marijke C C Sachweh; Sonia Laín
Journal:  Cell Cycle       Date:  2012-05-01       Impact factor: 4.534

7.  Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Authors:  Rosa Lapalombella; Qingxiang Sun; Katie Williams; Larissa Tangeman; Shruti Jha; Yiming Zhong; Virginia Goettl; Emilia Mahoney; Caroline Berglund; Sneha Gupta; Alicia Farmer; Rajeswaran Mani; Amy J Johnson; David Lucas; Xiaokui Mo; Dirk Daelemans; Vincent Sandanayaka; Sharon Shechter; Dilara McCauley; Sharon Shacham; Michael Kauffman; Yuh Min Chook; John C Byrd
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

8.  Impaired p53 expression, function, and nuclear localization in calreticulin-deficient cells.

Authors:  Nasrin Mesaeli; Clark Phillipson
Journal:  Mol Biol Cell       Date:  2004-02-06       Impact factor: 4.138

9.  The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation.

Authors:  Pauline J van der Watt; Christopher P Maske; Denver T Hendricks; M Iqbal Parker; Lynette Denny; Dhirendra Govender; Michael J Birrer; Virna D Leaner
Journal:  Int J Cancer       Date:  2009-04-15       Impact factor: 7.396

10.  Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling.

Authors:  Jing-Yue Yao; Shu Xu; Yue-Ning Sun; Ye Xu; Qing-Long Guo; Li-Bin Wei
Journal:  Acta Pharmacol Sin       Date:  2021-06-29       Impact factor: 6.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.